The LLS Blog
Read about survivors, research, fundraising and advocacy.
Meet The Researcher: Dr. Christopher R. Flowers
In this Q&A, we are highlighting Dr. Christopher R. Flowers, MD, chair of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center and LLS National Board Member. Later this week, Dr. Flowers will be speaking on a timely panel about diversity in hematology clinical trials at AACR 2021.
Because You Volunteer, Your Impact Creates a Ripple Effect
At The Leukemia & Lymphoma Society (LLS), volunteers are our superheroes. Learn about the impact our volunteers help make possible in honor of National Volunteer Week 2021.
FDA Approves Novel Car T-Immunotherapy for the Treatment of Multiple Myeloma
Chimeric Antigen Receptor (CAR) T cell-therapy is on a roll. Today marks the seventh approval of CAR T therapy since the first approval in 2017.
Another First: FDA Approves Car T-Immunotherapy for Treatment of Aggressive Form of Indolent Non-Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphoma (FL) that has returned or worsened despite earlier treatment. FL is the most common slow-growing non-Hodgkin’s lymphoma and while the disease can generally be managed, reoccurrence is common.
Meet Three Women in Science Championing Myeloma Cures and Care
Annamaria Gulla, MD, Dana-Farber Cancer Institute, is an LLS Career Development Program Fellow. With support from LLS, Dr. Gulla is working to improve outcomes for multiple myeloma patients through the power of immunotherapy. Immunotherapy – harnessing the immune system to fight cancer – has become a mainstay in cancer treatment. One promising approach centers on the evidence that cancer cells dying from specific treatment can be recognized by the patient’s own immune system, triggering an immune response against the disease. Dr. Gulla aims to characterize the molecular mechanisms behind this process – called immunogenic cell death – in multiple myeloma.